Back to Agenda
Session 5, Part II: Panel Discussion - Next Steps
Session Chair(s)
Sara Torgal, MPHARM
Global Regulatory Policy Lead, DIA, Switzerland
Session 5, Part II: Panel Discussion - Next Steps
Speaker(s)
Mats G. Hansson
IMI PREFER Coordinator & Senior Professor of Biomedical Ethics, Uppsala University, Sweden
Panel discussion with the presence of:
Conny Berlin, MS
IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology, Novartis Pharma AG, Switzerland
Contributing Panelist
John F. P. Bridges, PHD
Professor, Departments of Biomedical Informatics, Ohio State University College of Medicine, United States
Contributing Panelist
Laura Lee Johnson, PHD
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER, FDA, United States
Contributing Panelist
Mireille Muller, DRSC, PHD, MSC
Regulatory Policy & Intelligence Director, Novartis Pharma AG, Switzerland
Contributing Panelist
Jürgen Kübler, PHD
Owner, Quantitative Scientific Consulting, Germany
Contributing Panelist
Antonella Cardone
Director, Cancer Patients Europe, Belgium
Contributing Panelist
Have an account?